The collaboration will evaluate Celera’s numerous genetic findings in liver diseases, including the Cirrhosis Risk Score, in the Geisinger bank of more than 600 liver tissue and blood case-control samples donated from patients who have undergone bariatric weight loss surgery.
Bryan Allinson, director of Geisinger Ventures, said: “This academic entrepreneurial collaboration will help advance personalized medicine to practical clinical use, which is all part of Abigail Geisinger’s mission to make patient care ‘The Best’.”